Its main mechanism involves the stimulation of angiogenesis via the VEGF-eNOS-NO pathway, fibroblast migration, and type I collagen synthesis
Other additions to Category 1 include ruxolitinib phosphate, a JAK1and JAK2 inhibitor currently commercially available orally and topically for conditions such as myelofibrosis or atopic dermatitis respectively and dimercaprol,a chelating drug currently commercially-available as an injectable
Certain individuals face higher risk, including those with pre-existing liver disease, older adults, patients taking multiple medicines that affect the liver, and those with previous antibiotic-related liver reactions
This compound has a molecular weight of approximately 319.85 g/mol, making it relatively lightweight yet highly effective in its various applications
However, side effects can still occur